<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724357</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00082377</org_study_id>
    <nct_id>NCT03724357</nct_id>
  </id_info>
  <brief_title>Blood Donor CVD 9000</brief_title>
  <official_title>Blood Donor CVD 9000: Collection of Blood for In Vitro Studies From Healthy Adults Who Have Received Oral Cholera Vaccine (CVD 103-HgR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized study. Volunteers will be vaccinated with the oral&#xD;
      cholera vaccine, Vaxchora. Vaxchora has been licensed by the Food and Drug Administration&#xD;
      (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood&#xD;
      specimens over a follow-up time period of up to eight years. The specimens obtained in this&#xD;
      clinical research study will be used to further the investigator's understanding of the&#xD;
      protective immunological mechanisms that can be elicited systemically and may be applicable&#xD;
      to other enteric pathogens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2018</start_date>
  <completion_date type="Anticipated">October 2038</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Volunteers who choose to take part in this study will receive the licensed FDA-approved Oral Cholera Vaccine (Vaxchora).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>approximately 10 years</time_frame>
    <description>Percentage of responders by four-fold increase in vibriocidal antibody titers between pre- and post-immunization time-points.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cholera Vaccination</condition>
  <arm_group>
    <arm_group_label>Vaccination with Oral Cholera Vaccine (Vaxchora)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers receive immunization with Vaxchora cholera vaccine. Blood draws are performed at subsequent visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaxchora</intervention_name>
    <description>One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.</description>
    <arm_group_label>Vaccination with Oral Cholera Vaccine (Vaxchora)</arm_group_label>
    <other_name>CVD 103-HgR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age 18 years to 64 years at the time of enrollment&#xD;
&#xD;
          -  2. Good general health as determined by a screening evaluation within 28 days before&#xD;
             blood donation or vaccination&#xD;
&#xD;
          -  3. Provides written informed consent prior to initiation of any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of any of the following medical conditions:&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Cancer in past 5 years (except for basal cell carcinoma of the skin and cervical&#xD;
                  carcinoma in situ)&#xD;
&#xD;
               -  Heart disease (e.g., hospitalization for a heart attack, coronary artery bypass&#xD;
                  graft, arrhythmia, or syncope, within past 5 years. Current symptoms of heart&#xD;
                  disease, such as dyspnea, angina, or orthopnea)&#xD;
&#xD;
               -  Recurrent infections (e.g., more than 3 hospitalizations for invasive bacterial&#xD;
                  infections such as pneumonia or meningitis)&#xD;
&#xD;
               -  Current drug or alcohol abuse&#xD;
&#xD;
               -  Active ulcer disease or ongoing intestinal condition&#xD;
&#xD;
               -  Treatment for anemia in last 6 months&#xD;
&#xD;
               -  Treatment with anti-malarial drugs within ten days prior to study vaccination&#xD;
&#xD;
               -  Treatment with antibiotics within 14 days prior to study vaccination&#xD;
&#xD;
               -  Immunodeficiency or immunosuppression from illness or treatment&#xD;
&#xD;
          -  2. Close contact within 7 days following study vaccination with a person who has an&#xD;
             immunodeficiency or immunosuppression from illness or treatment&#xD;
&#xD;
          -  3. History of cholera infection or cholera vaccination&#xD;
&#xD;
          -  4. Any of the following complete blood count (CBC) abnormalities during screening:&#xD;
&#xD;
               -  white blood cells (WBC) &lt;0.81 x lower limit of normal (LLN) or &gt; 1.09 x upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Hemoglobin &lt;0.91 x LLN or &gt;1.18 x ULN (women) or &lt;0.92 x LLN or &gt;1.18 x ULN (men)&#xD;
&#xD;
               -  Platelet count &lt;0.8 x LLN or &gt; 1.2 x ULN&#xD;
&#xD;
          -  5. Any of the following laboratory abnormalities during screening:&#xD;
&#xD;
               -  serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic&#xD;
                  transaminase (SGPT) &gt;1.5 times normal&#xD;
&#xD;
               -  Positive serology for HIV antibody&#xD;
&#xD;
          -  6. Poor peripheral venous access for blood donation&#xD;
&#xD;
          -  7. Other condition that the opinion of the investigator would jeopardize the safety or&#xD;
             rights of a volunteer participating in the trial or interfere with the scientific&#xD;
             integrity of study&#xD;
&#xD;
          -  8. Positive urine pregnancy test (HCG) on the day of vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robin Barnes, CRNP</last_name>
    <phone>410-706-6156</phone>
    <email>rbarnes@som.umaryland.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Maryland, Baltimore, Center for Vaccine Development and Global Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Barnes, CRNP</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Monica McArthur, MD PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholera</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

